Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Zhejiang Xinguang Pharmaceutical Co., Ltd. specializes in the production of active pharmaceutical ingredients (APIs) and intermediates, primarily serving the Chinese and international markets. The company differentiates itself through its strong R&D capabilities and a focus on high-margin specialty drugs, which are less susceptible to price competition.
Zhejiang Xinguang generates revenue through the sale of APIs and finished pharmaceutical products, leveraging its R&D to develop proprietary formulations that command premium pricing. The company's competitive advantages include a robust supply chain, low-cost production capabilities, and a strong regulatory compliance record that enhances its market access.
Regulatory approvals for new drugs
Changes in pricing policies for pharmaceuticals in China
Market penetration in international markets
R&D pipeline advancements and successful trials
Regulatory changes impacting drug pricing and approvals
Technological disruption in drug development processes
Emergence of low-cost generic competitors
Increased competition from multinational pharmaceutical companies
Potential liquidity risks if cash flow does not improve
Dependence on continued R&D investment without immediate returns
moderate - The pharmaceutical industry is somewhat insulated from economic downturns, but demand can be affected by consumer spending on healthcare.
Low - The company has no debt, so rising interest rates do not impact financing costs. However, higher rates could affect consumer spending on healthcare products.
minimal - The company operates with a debt/equity ratio of 0.00, indicating no reliance on credit.
growth - Investors are likely attracted to the potential for high returns from innovative drug development.
moderate - The stock has shown significant price fluctuations, as evidenced by a 22.5% decline over the past three months.
